Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.01796 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Matthew J Ehrhardt und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, St Jude Children's Research Hospital, Memphis, TN. Hauptthemen laut MEDLINE: Cancer Survivors, Neoplasms, Cardiomyopathies. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE To leverage baseline global longitudinal strain (GLS) and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) to identify childhood cancer survivors with a normal left ventricular ejection fraction (LVEF) at highest risk of future treatment-related cardiomyopathy. METHODS St Jude Lifetime Cohort participants ≥5 years from diagnosis, at increased risk for cardiomyopathy per the International Guideline Harmonization Group (IGHG), with an LVEF ≥50% on baseline echocardiography (n = 1,483) underwent measurement of GLS (n = 1,483) and NT-proBNP (n = 1,052; 71%). Multivariable Cox regression models estimated hazard ratios (HRs) and 95% CIs for postbaseline cardiomyopathy (modified Common Terminology Criteria for Adverse Events ≥grade 2) incidence in association with echocardiogram-based GLS (≥–18) and/or NT-proBNP (>age-sex-specific 97.5th percentiles). Prediction performance was assessed using AUC in models with and without GLS and NT-proBNP and compared using DeLong's test for IGHG moderate- and high-risk individuals treated with anthracyclines. RESULTS Among survivors (median age, 37.6; range, 10.2-70.4 years), 162 (11.1%) developed ≥grade 2 cardiomyopathy 5.1 (0.7-10.0) years from baseline assessment. The 5-year cumulative incidence of cardiomyopathy for survivors with and without abnormal GLS was, respectively, 7.3% (95% CI, 4.7 to 9.9) versus 4.4% (95% CI, 3.0 to 5.7) and abnormal NT-proBNP was 9.9% (95% CI, 5.8 to 14.1) versus 4.7% (95% CI, 3.2 to 6.2). Among survivors with a normal LVEF, abnormal baseline GLS and NT-proBNP identified anthracycline-exposed, IGHG-defined moderate-/high-risk survivors at a four-fold increased hazard of postbaseline cardiomyopathy (HR, 4.39 [95% CI, 2.46 to 7.83]; P < .001), increasing to a HR of 14.16 (95% CI, 6.45 to 31.08; P < .001) among survivors who received ≥250 mg/m 2 of anthracyclines. Six years after baseline, AUCs for individual risk prediction were 0.70 for models with and 0.63 for models without GLS and NT-proBNP ( P = .022). CONCLUSION GLS and NT-proBNP should be considered for improved identification of survivors at high risk for future cardiomyopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.
- Department of Public Health Sciences, University of Alberta, Edmonton, AB, Canada.
- Department of Medicine, University of Tennessee Health Science Center, Memphis, TN.
- Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, TN.
- Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN.
ORCID-Profile: Matthew J Ehrhardt, Qi Liu, Daniel A Mulrooney, Isaac B Rhea, Stephanie B Dixon, John T Lucas, Yadav Sapkota, Kyla Shelton, Kirsten K Ness, Deo Kumar Srivastava, Aaron McDonald, Leslie L Robison, Melissa M Hudson, Yutaka Yasui
Förderung
- NCI NIH HHS
Zitieren
APA
Ehrhardt, M. J., Liu, Q., Mulrooney, D. A., Rhea, I. B., Dixon, S. B., Lucas, J. T., Sapkota, Y., Shelton, K., Ness, K. K., Srivastava, D. K., McDonald, A., Robison, L. L., Hudson, M. M., Yasui, Y., & Armstrong, G. T. (2024). Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01796
Vancouver
Ehrhardt MJ, Liu Q, Mulrooney DA, Rhea IB, Dixon SB, Lucas JT, et al. Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01796
BibTeX
@article{Ehrhardt2024,
author = {Ehrhardt, Matthew J and Liu, Qi and Mulrooney, Daniel A and Rhea, Isaac B and Dixon, Stephanie B and Lucas, John T and Sapkota, Yadav and Shelton, Kyla and Ness, Kirsten K and Srivastava, Deo Kumar and McDonald, Aaron and Robison, Leslie L and Hudson, Melissa M and Yasui, Yutaka and Armstrong, Gregory T},
title = {Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.01796}
}
EUVIMED